drugset / Trial / NCT06184659
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis
RandomizedParallel-groupOpen-labelTreatment
Summary
The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.
Timeline
- Start
- 2025-06-26
- Primary completion
- 2028-06-30
- Completion
- 2029-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Meropenem | Small molecule | 1 g | Intravenous |
| Subject | Meropenem | Small molecule | 2 g | Intravenous |
| Comparator | Piperacillin | Small molecule | 4 g | Intravenous |
| Comparator | Tazobactam | Small molecule | 0.5 g | Intravenous |